+
データを開く
-
基本情報
登録情報 | データベース: PDB / ID: 8vc7 | ||||||
---|---|---|---|---|---|---|---|
タイトル | Crystal Structure of Human BTN2A1 ectodomain in complex with Antagonist 2A1.9 Fab | ||||||
![]() |
| ||||||
![]() | SIGNALING PROTEIN / Inhibitor / Complex / Antibody / Immune Recognition | ||||||
機能・相同性 | ![]() Butyrophilin (BTN) family interactions / regulation of cytokine production / lipid metabolic process / T cell receptor signaling pathway / signaling receptor binding / external side of plasma membrane / plasma membrane 類似検索 - 分子機能 | ||||||
生物種 | ![]() | ||||||
手法 | ![]() ![]() ![]() | ||||||
![]() | Ramesh, A. / Roy, S. / Adams, E. | ||||||
資金援助 | ![]()
| ||||||
![]() | ![]() タイトル: Mapping the extracellular molecular architecture of the pAg-signaling complex with α-Butyrophilin antibodies. 著者: Amrita Ramesh / Sobhan Roy / Tomasz Slezak / James Fuller / Hortencia Graves / Murad R Mamedov / Alexander Marson / Anthony A Kossiakoff / Erin J Adams / ![]() 要旨: Target cells trigger Vγ9Vδ2 T cell activation by signaling the intracellular accumulation of phospho-antigen metabolites (pAgs) through Butyrophilin (BTN)-3A1 and BTN2A1 to the Vγ9Vδ2 T cell ...Target cells trigger Vγ9Vδ2 T cell activation by signaling the intracellular accumulation of phospho-antigen metabolites (pAgs) through Butyrophilin (BTN)-3A1 and BTN2A1 to the Vγ9Vδ2 T cell receptor (TCR). An incomplete understanding of the molecular dynamics in this signaling complex hampers Vγ9Vδ2 T cell immunotherapeutic efficacy. A panel of engineered α-BTN3A1 and α-BTN2A1 antibody (mAb) reagents was used to probe the roles of BTN3A1 and BTN2A1 in pAg signaling. Modified α-BTN3A1 mAbs with increased inter-Fab distances establish that tight clustering of BTN3A1 is not necessary to stimulate Vγ9Vδ2 T cell activation, and that antagonism may occur through occlusion of a critical binding interaction between BTN3A1 and a yet unknown co-receptor. Finally, a panel of additional α-BTN2A1 antagonists utilize different biophysical mechanisms to compete with Vγ9Vδ2 TCRs for BTN2A1 binding. The complex structures of BTN2A1 ectodomain and Fabs from three antagonist mAbs provide molecular insights into BTN2A1 epitopes critical for pAg-signaling. | ||||||
履歴 |
|
-
構造の表示
構造ビューア | 分子: ![]() ![]() |
---|
-
ダウンロードとリンク
-
ダウンロード
PDBx/mmCIF形式 | ![]() | 255.2 KB | 表示 | ![]() |
---|---|---|---|---|
PDB形式 | ![]() | 202.7 KB | 表示 | ![]() |
PDBx/mmJSON形式 | ![]() | ツリー表示 | ![]() | |
その他 | ![]() |
-検証レポート
文書・要旨 | ![]() | 494.2 KB | 表示 | ![]() |
---|---|---|---|---|
文書・詳細版 | ![]() | 509 KB | 表示 | |
XML形式データ | ![]() | 49.8 KB | 表示 | |
CIF形式データ | ![]() | 65.7 KB | 表示 | |
アーカイブディレクトリ | ![]() ![]() | HTTPS FTP |
-関連構造データ
関連構造データ | ![]() 9dpeC C: 同じ文献を引用 ( |
---|---|
類似構造データ | 類似検索 - 機能・相同性 ![]() |
-
リンク
-
集合体
登録構造単位 | ![]()
| ||||||||
---|---|---|---|---|---|---|---|---|---|
1 | ![]()
| ||||||||
2 | ![]()
| ||||||||
単位格子 |
|
-
要素
#1: 抗体 | 分子量: 23258.783 Da / 分子数: 2 / 由来タイプ: 組換発現 詳細: Light chain of Herceptin Fab scaffold with CDR loops modified through phage-display evolution. (CDR1: VSSAV) (CDR2: IYSASSLY) (CDR3: SSSSLIT). N-terminal (S) residue is a linker/restriction ...詳細: Light chain of Herceptin Fab scaffold with CDR loops modified through phage-display evolution. (CDR1: VSSAV) (CDR2: IYSASSLY) (CDR3: SSSSLIT). N-terminal (S) residue is a linker/restriction enzyme artifact, disordered and not modeled. 由来: (組換発現) ![]() ![]() ![]() #2: 抗体 | 分子量: 24836.652 Da / 分子数: 2 / 由来タイプ: 組換発現 詳細: Heavy chain of Herceptin Fab scaffold with CDR loops modified through phage-display evolution. (CDR1: NLYSSSI) (CDR2: YIYPSSGYTS) (CDR3: YYYTRGYPDGMDY). N-terminal (EISE) is a ...詳細: Heavy chain of Herceptin Fab scaffold with CDR loops modified through phage-display evolution. (CDR1: NLYSSSI) (CDR2: YIYPSSGYTS) (CDR3: YYYTRGYPDGMDY). N-terminal (EISE) is a linker/restriction enzyme artifact and first residue of Fab, and disordered and not modeled. Middle (SSKSTSG) and C-terminal (KSCDKTHT) residues were disordered and not modeled. 由来: (組換発現) ![]() ![]() ![]() #3: タンパク質 | 分子量: 25725.307 Da / 分子数: 2 / Mutation: C219S / 由来タイプ: 組換発現 詳細: BTN2A1 ectodomain with C219S mutation, and N- and C-terminal linkers. N-terminal (ADL) and C-terminal (VSPSGSGLEVLFQ) residues are disordered and not modeled. 3 glycans are denoted as NAG. 由来: (組換発現) ![]() ![]() #4: 糖 | ChemComp-NAG / 研究の焦点であるリガンドがあるか | N | Has protein modification | Y | |
---|
-実験情報
-実験
実験 | 手法: ![]() |
---|
-
試料調製
結晶 | マシュー密度: 3.22 Å3/Da / 溶媒含有率: 61.75 % / 解説: Overlapping large plates |
---|---|
結晶化 | 温度: 298 K / 手法: 蒸気拡散法, シッティングドロップ法 / pH: 8.3 詳細: Optimized well-G9 from Morpheus MIDAS MD1-76-HT Screen: - 0.1M Buffer System 3, pH 8.3 (Buffer System 3 1M Stock: 50.3% 1M Bicine, 49.7% 1M Tris) - 0.1M Carboxylic Acids Mix (Carboxylic Acids ...詳細: Optimized well-G9 from Morpheus MIDAS MD1-76-HT Screen: - 0.1M Buffer System 3, pH 8.3 (Buffer System 3 1M Stock: 50.3% 1M Bicine, 49.7% 1M Tris) - 0.1M Carboxylic Acids Mix (Carboxylic Acids Mix 1M Stock: 0.2M Sodium formate; 0.2M Ammonium acetate; 0.2M Sodium citrate tribasic dihydrate; 0.2M Potassium sodium tartrate tetrahydrate; 0.2M Sodium oxamate) - 20% Precipitant mix 1 (Precipitant mix 1 60% Stock: 40% v/v PEG500 MME; 20% w/v PEG20000) |
-データ収集
回折 | 平均測定温度: 100 K / Serial crystal experiment: N |
---|---|
放射光源 | 由来: ![]() ![]() ![]() |
検出器 | タイプ: DECTRIS PILATUS 6M / 検出器: PIXEL / 日付: 2023年8月31日 詳細: Mirror: Flat bent collimating Rh coated mirror, toroidal focussing mirror |
放射 | モノクロメーター: Si (111) double crystal / プロトコル: SINGLE WAVELENGTH / 単色(M)・ラウエ(L): M / 散乱光タイプ: x-ray |
放射波長 | 波長: 1.195 Å / 相対比: 1 |
反射 | 解像度: 2.76→39.46 Å / Num. obs: 49431 / % possible obs: 99.8 % / 冗長度: 8.9 % / Rmerge(I) obs: 0.258 / Rpim(I) all: 0.131 / Rrim(I) all: 0.29 / Net I/σ(I): 7.2 |
反射 シェル | 解像度: 2.76→2.85 Å / 冗長度: 9.3 % / Rmerge(I) obs: 1.424 / Num. unique obs: 4503 / Rpim(I) all: 0.711 / Rrim(I) all: 1.595 / % possible all: 100 |
-
解析
ソフトウェア |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
精密化 | 構造決定の手法: ![]()
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
溶媒の処理 | 減衰半径: 0.9 Å / VDWプローブ半径: 1.1 Å / 溶媒モデル: FLAT BULK SOLVENT MODEL | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
精密化ステップ | サイクル: LAST / 解像度: 2.76→39.46 Å
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
拘束条件 |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
LS精密化 シェル |
|